UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes

Clinical cancer research, 2007-06, Vol.13 (12), p.3731-3737

2007

Volltextzugriff (PDF)

In memoriam Michelle A. Rudek (1972–2023)

Clinical and translational science, 2024-01, Vol.17 (1), p.e13705-n/a

2024

Volltextzugriff (PDF)

Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B

Molecules (Basel, Switzerland), 2022-10, Vol.27 (20), p.6815

2022

Volltextzugriff (PDF)

Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors

Pharmaceutics, 2020-09, Vol.12 (9), p.856

2020

Volltextzugriff (PDF)

DNA methyltransferase inhibitor exposure–response: Challenges and opportunities

Clinical and translational science, 2023-08, Vol.16 (8), p.1309-1322

2023

Volltextzugriff (PDF)

Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia

Journal of clinical oncology, 2011-08, Vol.29 (24), p.3293-3300

2011

Volltextzugriff (PDF)

Author Correction: Increased renal elimination of endogenous and synthetic pyrimidine nucleosides in concentrative nucleoside transporter 1 deficient mice

Nature communications, 2023-06, Vol.14 (1), p.3335-3335, Article 3335

2023

Volltextzugriff (PDF)

Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib

JNCI : Journal of the National Cancer Institute, 2006-12, Vol.98 (23), p.1739-1742

2006

Volltextzugriff (PDF)

Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese

Journal of clinical oncology, 2007-10, Vol.25 (30), p.4707-4713

2007

Volltextzugriff (PDF)

Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography–tandem mass spectrometry

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2010-11, Vol.878 (29), p.3033-3038

2010

Volltextzugriff (PDF)

Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors

Journal of clinical oncology, 2008-12, Vol.26 (34), p.5504-5510

2008

Volltextzugriff (PDF)

Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination

Pharmaceutics, 2022-03, Vol.14 (4), p.694

2022

Volltextzugriff (PDF)

TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion

Cancers, 2022-12, Vol.15 (1), p.29

2022

Volltextzugriff (PDF)

DNA Methylation‐Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia

Clinical and translational science, 2021-01, Vol.14 (1), p.137-142

2021

Volltextzugriff (PDF)

Boosting the oral bioavailability of anticancer drugs through intentional drug–drug interactions

Basic & clinical pharmacology & toxicology, 2022-01, Vol.130 (S1), p.23-35

2022

Volltextzugriff (PDF)

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors

Cancer research (Chicago, Ill.), 2004-12, Vol.64 (24), p.9139-9143

2004

Volltextzugriff (PDF)

Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice

Clinical and translational science, 2019-07, Vol.12 (4), p.400-407

2019

Volltextzugriff (PDF)

CYP3A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors

JNCI : Journal of the National Cancer Institute, 2006-12, Vol.98 (23), p.1714-1723

2006

Volltextzugriff (PDF)

In Memoriam Michelle A. Rudek (1972–2023)

Clinical pharmacology and therapeutics, 2024-02, Vol.115 (2), p.181-182

2024

Volltextzugriff (PDF)

Ontogeny and Sorafenib Metabolism

Clinical cancer research, 2012-10, Vol.18 (20), p.5788-5795

2012

Volltextzugriff (PDF)

A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors

Clinical cancer research, 2009-10, Vol.15 (19), p.6241-6249

2009

Volltextzugriff (PDF)

A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug–Drug Interaction Liabilities

Pharmaceutics, 2022-09, Vol.14 (9), p.1933

2022

Volltextzugriff (PDF)

Irinotecan Pathway Genotype Analysis to Predict Pharmacokinetics

Clinical cancer research, 2003-08, Vol.9 (9), p.3246-3253

2003

Volltextzugriff (PDF)

Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib

Clinical cancer research, 2007-12, Vol.13 (24), p.7394-7400

2007

Volltextzugriff (PDF)

Activated Pregnenolone X-Receptor Is a Target for Ketoconazole and Its Analogs

Clinical cancer research, 2007-04, Vol.13 (8), p.2488-2495

2007

Volltextzugriff (PDF)

1 – 25 von 203

Suche als RSS-Feed

Aktive Filter

ThemaAnimals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(197)
Mit Volltextzugriff
(193)

Publikationsform

Sprache

Englisch
(203)

Erscheinungsjahr

n.n

Thema

Science & Technology
(132)
Life Sciences & Biomedicine
(130)
Humans
(119)
Oncology
(86)
Biological And Medical Sciences
(78)
Medical Sciences
(77)
Female
(71)
Male
(70)
Pharmacology. Drug Treatments
(64)
Middle Aged
(62)
Adult
(60)
Aged
(59)
Antineoplastic Agents
(52)
Neoplasms - Drug Therapy
(41)
Chemotherapy
(39)
Pharmacokinetics
(30)
Dose-Response Relationship, Drug
(28)
Antineoplastic Agents - Pharmacokinetics
(27)
Pharmacology & Pharmacy
(26)
Area Under Curve
(21)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes

In memoriam Michelle A. Rudek (1972–2023)

Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B

Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors

DNA methyltransferase inhibitor exposure–response: Challenges and opportunities

Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia

Author Correction: Increased renal elimination of endogenous and synthetic pyrimidine nucleosides in concentrative nucleoside transporter 1 deficient mice

Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib

Evaluation of Alternate Size Descriptors for Dose Calculation of Anticancer Drugs in the Obese

Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography–tandem mass spectrometry

Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors

Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination

TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion

DNA Methylation‐Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia

Boosting the oral bioavailability of anticancer drugs through intentional drug–drug interactions

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors

Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice

CYP3A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors

In Memoriam Michelle A. Rudek (1972–2023)

Ontogeny and Sorafenib Metabolism

A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors

A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug–Drug Interaction Liabilities

Irinotecan Pathway Genotype Analysis to Predict Pharmacokinetics

Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib

Activated Pregnenolone X-Receptor Is a Target for Ketoconazole and Its Analogs

Aktive Filter

Suchergebnisse filtern